Bristol Myers Squibb (BMY) Long-Term Investments (2009 - 2026)
Bristol Myers Squibb (BMY) reported Long-Term Investments of $366.0 million for Q1 2026, up 6.4% year-over-year from $344.0 million in Q1 2025, and down 7.58% on a QoQ basis from $396.0 million in Q4 2025.
Bristol Myers Squibb (BMY) has 17 years of Long-Term Investments data on file, last reported at $366.0 million in Q1 2026.
- Quarterly Long-Term Investments rose 6.4% year-over-year to $366.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $366.0 million (up 6.4% YoY) and the FY2025 annual result came in at $396.0 million, up 23.75% from the prior year.
- Long-Term Investments declined to $366.0 million in Q1 2026 per BMY's latest filing, from $396.0 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $406.0 million in Q3 2025 and bottomed at $320.0 million in Q4 2024.
- The 4-year median for Long-Term Investments is $360.5 million (2023), against an average of $359.0 million.
- The widest annual swing landed in 2024, when Long-Term Investments fell 12.09%; it then climbed 25.31% in 2025.
- Tracing BMY's Long-Term Investments over 4 years: stood at $364.0 million in 2023, then declined by 12.09% to $320.0 million in 2024, then grew by 23.75% to $396.0 million in 2025, then retreated by 7.58% to $366.0 million in 2026.
- Per Business Quant, the three latest BMY Long-Term Investments figures stand at $366.0 million (Q1 2026), $396.0 million (Q4 2025), and $406.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.12 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 268.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 983.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 1.63 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 366.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 366.00 Mn |
| Dec 31, 2025 | 396.00 Mn |
| Sep 30, 2025 | 406.00 Mn |
| Jun 30, 2025 | 346.00 Mn |
| Mar 31, 2025 | 344.00 Mn |
| Dec 31, 2024 | 320.00 Mn |
| Sep 30, 2024 | 324.00 Mn |
| Jun 30, 2024 | 357.00 Mn |
| Mar 31, 2024 | 367.00 Mn |
| Dec 31, 2023 | 364.00 Mn |
| Sep 30, 2021 | 46.00 Mn |
| Jun 30, 2021 | 143.00 Mn |
| Mar 31, 2021 | 288.00 Mn |
| Dec 31, 2020 | 433.00 Mn |
| Sep 30, 2020 | 495.00 Mn |
| Jun 30, 2020 | 523.00 Mn |
| Mar 31, 2020 | 651.00 Mn |
| Dec 31, 2019 | 767.00 Mn |
| Sep 30, 2019 | 925.00 Mn |
| Jun 30, 2019 | 994.00 Mn |
| Mar 31, 2019 | 1.23 Bn |
| Dec 31, 2018 | 1.78 Bn |
| Sep 30, 2018 | 2.02 Bn |
| Jun 30, 2018 | 2.12 Bn |
| Mar 31, 2018 | 2.25 Bn |
| Dec 31, 2017 | 2.48 Bn |
| Sep 30, 2017 | 2.53 Bn |
| Jun 30, 2017 | 2.58 Bn |
| Mar 31, 2017 | 2.69 Bn |
| Dec 31, 2016 | 2.72 Bn |
| Sep 30, 2016 | 3.04 Bn |
| Jun 30, 2016 | 3.28 Bn |
| Mar 31, 2016 | 3.69 Bn |
| Dec 31, 2015 | 4.66 Bn |
| Sep 30, 2015 | 4.63 Bn |
| Jun 30, 2015 | 4.63 Bn |
| Mar 31, 2015 | 4.28 Bn |
| Dec 31, 2014 | 4.41 Bn |
| Sep 30, 2014 | 4.33 Bn |
| Jun 30, 2014 | 3.88 Bn |
| Mar 31, 2014 | 3.56 Bn |
| Dec 31, 2013 | 3.75 Bn |
| Sep 30, 2013 | 3.62 Bn |
| Jun 30, 2013 | 3.22 Bn |
| Mar 31, 2013 | 3.24 Bn |
| Dec 31, 2012 | 3.52 Bn |
| Sep 30, 2012 | 3.70 Bn |
| Jun 30, 2012 | 3.73 Bn |
| Mar 31, 2012 | 3.59 Bn |
| Dec 31, 2011 | 2.91 Bn |
| Sep 30, 2011 | 2.82 Bn |
| Jun 30, 2011 | 2.73 Bn |
| Mar 31, 2011 | 3.07 Bn |
| Dec 31, 2010 | 2.68 Bn |
| Dec 31, 2009 | 1.37 Bn |
| Sep 30, 2009 | 1.20 Bn |
| Jun 30, 2009 | 983.00 Mn |